ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2020

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

Bart Van Wijmeersch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.